|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Atrophic Vaginitis | |||||
| Atrophy | |||||
| Vaginitis | |||||
| 2 | More general conditions related to this trial | ||||
| Genital Diseases, Female | |||||
| Pathological Conditions, Anatomical | |||||
| Vaginal Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| PVC (daily for 21 days, 7 days off) | |||||
| PVC (twice weekly) | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Estrogens, Conjugated (USP) | |||||
| 5 | More general drug interventions related to this trial | ||||
| Estrogens | |||||
| Hormones | |||||
| Hormones, Hormone Substitutes, and Hormone Antagonists | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 6 | Sponsors listed in this trial | ||||
| Wyeth | |||||